Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
Martine ZimmermannDirector | Ligand PharmaceuticalsLGND | 1,200 sh | $342,000 | 09/10 | Filed 09/10 |
Andrew ReardonOfficer | Ligand PharmaceuticalsLGND10b5-1 plan | 15,000 sh | $4,303,800 | 09/03 | Filed 09/03 |
Espinoza OctavioOfficer | Ligand PharmaceuticalsLGND10b5-1 plan | 31,641 sh | $9,136,338.75 | 08/12 | Filed 08/12 |
Jason HaasDirector | Ligand PharmaceuticalsLGND | 7,138 sh | $2,090,061.99 | 08/12 | Filed 08/12 |
Andrew ReardonOfficer | Ligand PharmaceuticalsLGND10b5-1 plan | 10,000 sh | $3,160,900 | 07/01 | Filed 07/01 |
Stephen L. SabbaDirector | Ligand PharmaceuticalsLGND | 2,145 sh | $544,830 | 06/16 | Filed 06/16 |
Jason HaasDirector | Ligand PharmaceuticalsLGND | 6,461 sh | $1,654,016 | 06/12 | Filed 06/12 |
Jason AryehDirector | Ligand PharmaceuticalsLGND | 4,500 sh | $1,124,879.82 | 06/11 | Filed 06/11 |
Jason AryehDirector | Ligand PharmaceuticalsLGND | 500 sh | $124,980.42 | 06/10 | Filed 06/10 |
John L. LamattinaDirector | Ligand PharmaceuticalsLGND | 4,519 sh | $1,133,710.9 | 06/10 | Filed 06/10 |
Jason AryehDirector | Ligand PharmaceuticalsLGND | 5,000 sh | $1,246,750 | 06/10 | Filed 06/10 |
John W. KozarichDirector | Ligand PharmaceuticalsLGND | 1,575 sh | $352,012.5 | 05/13 | Filed 05/13 |
John W. KozarichDirector | Ligand PharmaceuticalsLGND | 459 sh | $102,816 | 05/12 | Filed 05/12 |
John W. KozarichDirector | Ligand PharmaceuticalsLGND10b5-1 plan | 467 sh | $107,349.29 | 05/01 | Filed 05/01 |
John W. KozarichDirector | Ligand PharmaceuticalsLGND10b5-1 plan | 467 sh | $95,034.5 | 04/01 | Filed 04/01 |
Stephen L. SabbaDirector | Ligand PharmaceuticalsLGND | 1,000 sh | $207,872.7 | 03/23 | Filed 03/23 |
Espinoza OctavioOfficer | Ligand PharmaceuticalsLGND10b5-1 plan | 3,057 sh | $648,970.53 | 03/11 | Filed 03/11 |
John L. LamattinaDirector | Ligand PharmaceuticalsLGND | 2,161 sh | $433,842.36 | 03/06 | Filed 03/06 |
Andrew ReardonOfficer | Ligand PharmaceuticalsLGND10b5-1 plan | 20,000 sh | $4,084,800 | 03/04 | Filed 03/04 |
Espinoza OctavioOfficer | Ligand PharmaceuticalsLGND10b5-1 plan | 13,423 sh | $2,741,513.52 | 03/04 | Filed 03/04 |
